Avoid common mistakes on your manuscript.
Correction: Rheumatology and Therapy (2023) 10:1255–1276 https://doi.org/10.1007/s40744-023-00576-8
In Table 5 of this article, the frequencies (%) for serious adverse events (SAEs) within the rheumatoid arthritis (RA) section for the age ≥ 65 years, female sex, and male sex patient subgroups were published with incorrect values of 77.48, 59.00, and 58.49, respectively. The correct values are 21.27, 16.50, and 19.06, respectively. The first three rows of the ‘RA’ section from the corrected table 5 are provided below.
Excerpt from Table 5
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Burmester, G.R., Coates, L.C., Cohen, S.B. et al. Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Rheumatol Ther 11, 221–222 (2024). https://doi.org/10.1007/s40744-023-00615-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40744-023-00615-4